Dr Lal PathLabs Q4 FY26: Revenue up 17%, PAT down

Market reaction: sharp moves after the results

Dr. Lal PathLabs’ share price saw a sharp reaction after the company reported its Q4 FY26 numbers. One market update said the stock surged 17.87% to Rs 1,612.60 following the quarterly performance. A separate trading update noted the stock closed 2.1% lower at Rs 1,368.10 on the BSE on Thursday. Together, the data points show the stock remained volatile around the results day. The company is a provider of diagnostic and related healthcare tests and services in India. The results were first published on May 04, 2026 at 11:50 AM IST.

Headline numbers for Q4 FY26

On a consolidated basis, Dr Lal PathLabs reported revenue of Rs 703 crore in Q4 FY26, up 16.6% year-on-year. EBITDA rose 10.5% year-on-year to Rs 187 crore during the quarter. The EBITDA margin moderated to 26.6% from 28.1% in the year-ago period, pointing to margin compression despite higher revenue. Profit before tax (PBT) came in at Rs 160 crore, up 4.2% year-on-year. Reported net profit for the quarter was Rs 132 crore, down 15.1% year-on-year.

Why profit fell despite revenue growth

The company linked the year-on-year decline in reported Q4 profit to a one-time tax benefit recorded in the prior year. According to the company’s investor presentation, Q4 FY25 included a tax benefit of Rs 41 crore arising from the liquidation of its wholly owned subsidiary, Suburban Diagnostics (India) Private Limited (SDPL). Without this one-off item, the normalised net profit for Q4 FY25 would be Rs 115 crore, as per the presentation. On that normalised base, Q4 FY26 profit would represent a 15.1% growth, as stated in the report. This context is important because the headline year-on-year profit decline is not purely driven by operating performance.

Operating drivers: volumes and test mix

Revenue growth in Q4 FY26 was described as sample volume-driven. The company reported sample volume growth of 12% year-on-year for the March quarter. Another set of management remarks cited sample volume growth of 12.9% in Q4 and 10.4% for FY26. Revenue per patient for Q4 FY26 was reported at Rs 956, up 7.8% compared with Rs 887 in Q4 FY25, supported by improvement in test and geographic mix. Tests per patient rose to 3.21 from 3.07 a year earlier. Management also referred to maintaining a calibrated pricing approach.

Costs rose across key lines

Alongside volume-led revenue growth, cost lines moved up year-on-year. Material expenses increased 14.4% to Rs 135 crore in Q4 FY26. Employee benefit expenses rose 18.3% to Rs 129 crore. Other expenses increased 17.1% to Rs 151 crore during the quarter. The report described these increases as reflecting continued investments in operations. The combination of rising costs and sustained investments helps explain why EBITDA margin softened even as EBITDA grew.

Full-year FY26 performance

For FY26, Dr Lal PathLabs reported net profit of Rs 510 crore, up 3.6% year-on-year. Revenue for the year was Rs 2,763 crore, up 12.2% year-on-year. Full-year EBITDA rose 8.2% to Rs 752 crore. The EBITDA margin moderated to 27.2% from 28.3% in the previous year. Full-year PBT was Rs 669 crore versus Rs 625 crore in FY25, with a PBT margin of 24.2%.

Margin picture: compression in Q4 and FY26

The company’s reported EBITDA margin fell to 26.6% in Q4 FY26 from 28.1% in Q4 FY25. For the full year, EBITDA margin moderated to 27.2% from 28.3% in FY25. Reported PAT margin for Q4 FY26 was 18.8%. Full-year PAT margin for FY26 was 18.4%, as shared in management commentary. These figures indicate that while growth remained healthy, profitability ratios were under pressure compared to the previous year.

Management commentary and one-off items

Ved Prakash Goel, Group CFO at Dr Lal PathLabs, said the company delivered a strong performance in Q4 and FY26, driven by healthy volume growth and an improved test mix, while maintaining a calibrated pricing approach. Management notes also referenced exceptional items across quarters. A one-time cost of Rs 30 crore related to the new labour code was accounted for in Q3 FY26, as per the commentary. Separately, the one-time tax benefit of Rs 41 crore was recorded in Q4 FY25 due to the voluntary liquidation of Suburban Diagnostics. The company also stated that its preventive healthcare brand ‘Swasth’ contributed 27% to total revenue in FY26.

Key numbers at a glance

What investors may track next

The Q4 FY26 results underline a combination of volume-led growth and softer margins. Investors will likely watch whether cost growth moderates relative to revenue as operational investments continue. They may also track how the company sustains improvements in test mix and revenue per patient, both of which were highlighted in management remarks. The impact of one-off items will remain relevant when comparing profits across periods, especially the prior-year tax benefit. Any future disclosures around expansion plans or additional investments could further shape market expectations.